Aon PLC vs Novo Nordisk A/S — how do they compare? Aon PLC trades at $352.12 (market cap $75.61B), while Novo Nordisk A/S trades at $46.17 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.7× Aon PLC's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| AON | NVO | |
|---|---|---|
Market Cap | $75.61B | $207.85B |
Sector | Financials | Health |
52-Week High | $381.26 | $63.98 |
52-Week Low | $308.22 | $35.29 |
Enterprise Value | $90.22B | $222.55B |
Dividend Yield | 0.92% | 3.81% |
Signals from Pluang's Aura AI — not financial advice
AON trades at $351.56, down 1.52% on the day, with a neutral technical signal and strong fundamentals including a 22.27% net income margin and consistent earnings beats. The stock shows robust profitability with ROE of 44.88% and revenue growth to $17.18B in 2025, though valuation multiples like a P/E of 19.65 and P/S of 4.37 reflect premium pricing. Recent news highlights institutional buying and Q2 2026 earnings beat, with organic revenue growth of 5% supporting positive sentiment.
Outlook remains favorable given earnings momentum and analyst consensus price target of $410, but risks include high valuation sensitivity and debt levels. The stock offers growth exposure with upside potential, balanced by execution risks in a competitive insurance brokerage sector.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Trailing returns across standard periods
Latest headlines on both assets
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →